Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study

European Journal of Cancer

Volumn 42, Issue 17, 2006, Pages 2968-2975

  Geisler, J ^a   Lonning P E ^a   Krag, L E ^b   Lokkevik E ^c   Risberg, T ^d   Hagen, A I ^e   Schlichting, E ^c   Lien, E A ^a   Ofjord E S ^f   Eide, G E ^a   Polli, A ^g   di Salle, E ^g   Paolini, J ^g  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^f Center for Clinical Trials   (Norway)

^g PFIZER INC   (United States)

Author keywords

Adjuvant therapy; Aromatase; Bone metabolism; Breast cancer; Exemestane; Lipids; Oestrogen; Vitamin D

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; EXEMESTANE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; FEMUR NECK; FOLLOW UP; HOT FLUSH; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; LIVER FUNCTION TEST; LUMBAR SPINE; MAJOR CLINICAL STUDY; NAUSEA; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VITAMIN BLOOD LEVEL;

ANDROSTADIENES; AROMATASE INHIBITORS; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; BONE AND BONES; BONE DENSITY; BONE REMODELING; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GONADAL STEROID HORMONES; HOMOCYSTEINE; HUMANS; LIPIDS; MIDDLE AGED; POSTMENOPAUSE; VITAMIN D; WITHHOLDING TREATMENT;

EID: 33750522464     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.07.005     Document Type: Article

References (36)

1. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 9453 (2005) 60-62
2. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 19 (2003) 1793-1802
3. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 11 (2004) 1081-1092
4. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23 22 (2005) 5138-5147
5. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 9484 (2005) 455-462
6. Geisler J., King N., Anker G., et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4 (1998) 2089-2093
7. Geisler J., Haynes B., Anker G., Dowsett M., and Lønning P.E. Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study. J Clin Oncol 20 (2002) 751-757
8. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 26 (2005) 2747-2757
9. Geisler J., and Lønning P.E. Aromatase inhibitors as adjuvant treatment of breast cancer. Crit Rev Oncol Hematol 57 (2006) 53-61
10. Powles T.J., Hickish T., Kanis J.A., Tidy A., and Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14 (1996) 78-84
11. Love R.R., Wiebe D.A., Feyzi J.M., Newcomb P.A., and Chappell R.J. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 86 20 (1994) 1534-1539
12. Lien E.A., Solheim E., and Ueland P.M. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 51 (1991) 4837-4844
13. Lønning P.E., Geisler J., Krag L.E., et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23 22 (2005) 5126-5137
14. World, Health Organisation. Assessment of fracture risk and application to screening for postmenopausal osteoporosis. Geneva: WHO; 1994.
15. Hollis B.W., and Wagner C.L. Normal serum vitamin D levels. N Engl J Med 352 5 (2005) 515-516
16. Heaney R.P., Dowell M.S., Hale C.A., and Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 22 2 (2003) 142-146
17. Hollis B.W. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 135 2 (2005) 317-322
18. Kanis J.A., Johnell O., De Laet C., Jonsson B., Oden A., and Ogelsby A.K. International variation in hip fracture probabilities: implications for risk assessment. J Bone Mineral Res 17 (2002) 1237-1244
19. Cauley J.A., Thompson D.E., Ensrud K.C., Scott J.C., and Black D. Risk of mortality following clinical fractures. Osteoporos Int 11 7 (2000) 556-561
20. Subar M., Goss P., Thomsen T., and Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors (Als) on markers of bone turnover and lipid metabolism in healthy volunteers. Am Soc Clin Oncol 23 (2004) 734
21. Coleman R., Banks L., Girgis S., et al. Skeletal effect of exemestane in the Intergropup Exemestane Study (IES) - 2 year bone mineral density (BMD) and bone biomarker data. Breast Cancer Res Treat 94 S1 (2005) S233
22. Atalay G., Dirix L., Biganzoli L., et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann Oncol 15 2 (2004) 211-217
23. Engan T., Krane J., Johannessen D.C., Lønning P.E., and Kvinnsland S. Plasma changes in breast cancer patients during endocrine therapy - lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat 36 (1995) 287-297
24. Markopoulos C., Polychronis A., Zobolas V., et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 93 1 (2005) 61-66
25. Markopoulos C., Chrissochou M., Michailidou A., et al. Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anti-Cancer Drugs 16 8 (2005) 879-883
26. Boden W.E. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: Assessing the data from Framingham to the Veterans Affairs high-density lipoprotein intervention trial. Am J Cardiol 86 12A (2000) 19L-22L
27. Gotto A.M. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 144 (2002) 533-542
28. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 280 (1998) 605-613
29. Alexander K.P., Newby L.K., Hellkamp A.S., et al. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J Amer Coll Cardiol 38 1 (2001) 1-7
30. Viscoli C.M., Brass L.M., Kernan W.N., Sarrel P.M., Suissa S., and Horwitz R.I. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345 17 (2001) 1243-1249
31. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial. Jama 291 14 (2004) 1701-1712
32. Harman S.M., Naftolin F., Brinton E.A., and Judelson D.R. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann NY Acad Sci 1052 (2005) 43-56
33. Wasan K.M., Goss P.E., Pritchard P.H., et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 16 5 (2005) 707-715
34. Geisler J., and Lønning P.E. Aromatase inhibition - translation into a successful therapeutic approach. Clin Cancer Res 11 (2005) 2809-2821
35. Lønning P.E., Bajetta E., Murray R., et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 18 11 (2000) 2234-2244
36. Johannessen D.C., Engan T., di Salle E., et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 3 (1997) 1101-1108